Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Administrative Sanction on MTPC Too Harsh: Mr Gohara
April 26, 2010
- Korosho Asks 4 Companies to Develop IPV
April 26, 2010
- Toho HD to Merge Asucome in October
April 26, 2010
- Carna Biosciences' R&D Project to Be Funded by NIBIO
April 26, 2010
- Mochida Terminates License Agreement for TRPV1 Antagonists with Wyeth
April 26, 2010
- CMIC Licenses L-FABP Diagnostic Technology to Genzyme
April 26, 2010
- AnGes to Discuss Licensing of ILTS with MEDRx
April 26, 2010
- BI Successfully Completes Tender Offer on SSP
April 26, 2010
- GSK Opens Rare Diseases Medicine Development Center in Japan
April 26, 2010
- Kenko.com Appeals Aiming at Online Sale of Classes 1, 2 OTC Drugs
April 26, 2010
- Shionogi's Demand Rejected in Flomox Patent Litigation
April 26, 2010
- Kenporen Members to Report Record-High Deficit of ¥660 Bil.
April 26, 2010
- BI Launches Global Venture Fund
April 26, 2010
- Isentress Recommended for Lack of Effects on Lipids: Dr Hanabusa
April 26, 2010
- Biomedical Cluster Kansai Changes Its Operation Systems
April 26, 2010
- Only 12.6% of the Elderly Aware of Pneumococcal Vaccines
April 26, 2010
- 14 New Products Approved by Korosho
April 26, 2010
- 3,787 Pass National Exam for Pharmacists with Pass Rate of 56.35%
April 26, 2010
- FPMAJ to Determine Measures to Enhance Ethical Compliance
April 26, 2010
- Bayer to Increase Sales of New Drugs to 50% of Total Sales
April 26, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…